Evidence map›Paper›PMID 41488865›Full record

ArticleInternational journal of nanomedicine2025

Cellular Synthesis of Targeted Ultrasound Molecular Imaging Probe and Its Application in Prostate Cancer Diagnosis.

Zhenzhou Li, Tingting Liu, Tao Cui, Xiong Shen, Chenxing Liu, Fei Yan

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhenzhou Li *Department of Ultrasound, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518061, People's Republic of China.
Tingting Liu *Department of Ultrasound, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518061, People's Republic of China.
Tao Cui *Nuclear Medicine Department, Shenzhen Hezheng Hospital, Shenzhen, 518055, People's Republic of China.
Xiong ShenDepartment of Ultrasound, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518061, People's Republic of China.ORCID 0009-0000-8193-9973
Chenxing LiuState Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, People's Republic of China.
Fei YanState Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The traditional construction of targeted ultrasound molecular imaging probes relies on multistep chemical synthesis strategies, which are time-consuming and inefficient, thereby limiting technological advancements. To address this, we developed a novel genetic engineering approach for biosynthesizing targeted nanoprobes for prostate cancer diagnosis. Materials and Methods: The anti-PSMA nanobody-encoding gene was fused to the C-terminus of the gas vesicle structural protein gene GvpC and cloned into a pBV220 plasmid with a hyperthermia-responsive gene expression circuit. This recombinant plasmid was transformed into Results: The biosynthesized PSMA-eGVs probes exhibited a uniform size (100-200 nm) and demonstrated excellent targeting capability in prostate cancer cells. In vivo studies confirmed effective tumor vascular penetration and specific binding with PSMA-positive tumor cells, resulting in significantly stronger acoustic signals than the non-targeted EGFP-eGVs controls. Conclusion: This cellular synthesis strategy enables efficient production of targeted ultrasound molecular imaging probes through genetically engineering technology, providing a promising platform for precision cancer diagnostics.

Indexed as

Molecular ImagingMolecular ProbesProstatic NeoplasmsAnimalsAntigens, SurfaceCell Line, TumorEscherichia coliGenetic EngineeringGlutamate Carboxypeptidase IIHumansMaleMiceSingle-Domain AntibodiesUltrasonographyAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IIMolecular ProbesSingle-Domain Antibodiescellular synthesisgas vesiclesprostate cancer diagnosistargeted ultrasound molecular imaging probeultrasound molecular imaging

Identifiers

PMID41488865
PMCPMC12764214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.